MedMira's Q3 FY2026 Financial Review and Market Expansion Efforts

MedMira Inc., based in Halifax, has announced its financial results for Q3 FY2026, ending April 30, 2026. The company is advancing the regulatory approval for its Multiplo® Complete Syphilis Antibody Test in Canada and international markets. The completion of the test's second phase of clinical trials promises to support further regulatory applications.

Revenue for the quarter increased significantly to $241,189 compared to $24,503 in Q2 FY2026, driven by product and service sales. Gross profit also saw a rise, hitting $176,409 in Q3. Despite these gains, operating expenses totaled $441,218, contributing to a net loss of $483,660, though an improvement from last year’s $657,552 loss.

MedMira worked on establishing its presence in Australia and EMEA markets under recognition agreements, aiming to bolster future growth. Assets decreased by $176,935, while liabilities increased by $306,725, leading to a higher working capital deficit of $365,147.